YB-1 protein correlates with high-risk tumor characteristics and response to high dose chemotherapy in breast cancer.

被引：0
|
作者：
Gluz, O.
Harbeck, N.
Kates, R. E.
Schmitt, M.
Mengele, K.
Royer, H-D
Eckstein, N.
Svjetlana, M.
Ting, E.
Poremba, C.
Nitz, U.
Diallo-Danebrock, R.
机构：
[1] Univ Dusseldorf, D-4000 Dusseldorf, Germany
[2] Tech Univ, Munich, Germany
[3] Caesar Inst, Bonn, Germany
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S136 / S136
页数：1
相关论文
共 50 条
  • [1] High-dose chemotherapy in high-risk breast cancer
    Price, LA
    LANCET, 1998, 352 (9139): : 1551 - 1552
  • [2] High-dose chemotherapy in high-risk breast cancer
    de Boer R.
    Breast Cancer Research, 2 (1)
  • [3] Y-BOX BINDING PROTEIN YB-1 IDENTIFIES HIGH-RISK PRIMARY BREAST CANCER PATIENTS BENEFITING FROM RAPIDLY CYCLED TANDEM HIGH-DOSE ADJUVANT CHEMOTHERAPY
    Gluz, O.
    Mengele, K.
    Schmitt, M.
    Kates, R.
    Diallo-Danebrock, R.
    Royer, H.
    Eckstein, N.
    Mohrmann, S.
    Nitz, U.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2009, 20 : 55 - 55
  • [4] Y-Box binding protein YB-1 identifies high-risk primary breast cancer patients benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy
    Schmitt, Manfred
    Gluz, Oleg
    Mengele, Karin
    Nitz, Ulrike
    Royer, Hans-Dieter
    Harbeck, Nadia
    CANCER RESEARCH, 2009, 69
  • [5] Y-Box-Binding Protein YB-1 Identifies High-Risk Patients With Primary Breast Cancer Benefiting From Rapidly Cycled Tandem High-Dose Adjuvant Chemotherapy
    Gluz, Oleg
    Mengele, Karin
    Schmitt, Manfred
    Kates, Ronald
    Diallo-Danebrock, Raihana
    Neff, Frauke
    Royer, Hans-Dieter
    Eckstein, Niels
    Mohrmann, Svjetlana
    Ting, Evelyn
    Kiechle, Marion
    Poremba, Christopher
    Nitz, Ulrike
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6144 - 6151
  • [6] High-dose chemotherapy in high-risk breast cancer - Reply
    Pusztai, L
    Hortobagyi, GN
    LANCET, 1998, 352 (9139): : 1552 - 1552
  • [7] High-dose chemotherapy for high-risk primary breast cancer
    Peters, WP
    Dansey, R
    Klein, J
    Berry, D
    ADJUVANT THERAPY OF CANCER VIII, 1997, 8 : 117 - 122
  • [8] High-dose chemotherapy in high-risk primary breast cancer
    Schmid, P
    Possinger, K
    ONKOLOGIE, 2002, 25 (02): : 112 - 120
  • [9] Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to a adjuvant chemotherapy in breast cancer
    Huang, JX
    Tan, PH
    Li, KB
    Matsumoto, K
    Tsujimoto, M
    Bay, BH
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 26 (03) : 607 - 613
  • [10] Discouraging news for high-dose chemotherapy in high-risk breast cancer
    Pusztal, L
    Hortobagyi, GN
    LANCET, 1998, 352 (9127): : 501 - 502
12345